(Originally posted 3/11/22) (Updated 3/13/22)
2022 has been a challenging year thus far for biotech investors with XBI down 27% YTD and down 42% over the last 52 weeks. More specifically for biopharma investors, smid-cap biopharma companies* are slightly up this week (+1.4%) but YTD these companies are down 26.6%. Many of these companies are trading at or below cash value, which creates opportunities for investors to pick up value plays. We analyzed our bpiq.com smid-cap database to identify micro, small and mid-cap biopharma companies trading below cash for possible investment opportunities for biopharma investors.
At BPIQ.com, we follow and analyze virtually all micro, small, and mid-cap biopharma companies. We not only update our clinical trial database on a daily basis, we track company information on a quarterly basis, such as current cash and short term market securities data as well as quarterly burn from operations. Here we analyze which companies are trading at or below their cash value.
Interestingly, about 1/4 of all micro, small and mid-cap biopharma companies (market cap of $100M - $10B) are trading near or below their cash. However, with respect to mid-caps, only one company in our database above $2B market cap is trading below cash (that is GLPG). Thus, not surprisingly, almost all biopharma companies trading below cash are micro-cap or small-cap companies (below $300M market cap).
Table 1 shows $200M to $2B market cap biopharma companies trading below cash. Table 2 presents micro cap biopharma companies with market caps below $200M trading below cash. One immediate result from the major biopharma downturn in the last year is that there are now around the same number of $200M - $2B market-cap biopharma companies in our database as those with market caps below $200M (275 vs. 270). Of the 275 $200M-$2B market cap biopharma companies, 11 are trading below cash. More dramatically, of the 270 micro-cap biopharma companies with market caps under $200M, 124 are trading below cash (46%).
Table 1 also includes the enterprise value for the $200M-$2B market-cap biopharma companies trading below cash value. Companies with a negative EV are companies whose cash is not the result of taking on a lot of debt. Thus, these mostly small-cap companies with a negative EV are some of the most interesting value plays, as the company has more cash on hand than their market cap + debt. And with a market cap still above $200M these companies are substantial enterprises with less risk generally than microcaps with a market cap below $200M.
Investors may want to peruse bpiq.com to analyze the clinical assets of these companies trading at or below cash and to check out their upcoming catalysts because there is a lot of upside in these companies if they can bring a clinical asset to approval. See our full forum post HERE for a deeper analysis, including information about which companies trading near cash have upcoming Mover events this year.
Table 1. Small cap biopharmas ($200M to $2B) trading at or below cash (GLPG added as it is the only company above $2B market cap trading below cash)
Note: Quarter identifies if cash values are traken from Q3 '21 or Q4 '21 SEC filings
Table 2. Micro cap biopharmas (under $200M) trading at or below cash
Note: Quarter identifies if cash values are traken from Q3 '21 or Q4 '21 SEC filings
تعليقات